The Food and Drug Administration has approved Viberzi (eluxadoline) and Xifaxan (rifaximin) to treat irritable bowel syndrome with diarrhea (IBS-D) in adults, the agency announced May 27.
Viberzi is...
Women with Crohn’s disease had about a 53% greater risk of developing cervical cancer compared with controls, and women with inflammatory bowel dise... More »
Women with Crohn’s disease had about a 53% greater risk of developing cervical cancer compared with controls, and women with inflammatory bowel dise... More »
Women with Crohn’s disease had about a 53% greater risk of developing cervical cancer compared with controls, and women with inflammatory bowel dise... More »
Room air hypoxemia was associated with greater post–liver transplant mortality in hepatopulmonary syndrome patients, according to Dr. David S. Goldberg and his colleagues.
On the other hand, HPS...
There is no significant difference between infliximab and adalimumab in Crohn’s disease, reported Dr. Mark T. Osterman and his colleagues in the May 1 issue of Clinical Gastroenterology and...
Oral budesonide is effective and safe for short-term treatment of collagenous colitis.
Indeed, the finding supports the recent recommendation by the European Microscopic Colitis Group to make...
Patients with chronic pancreatitis have a life expectancy that is roughly 8 years shorter than that of the general population.
Indeed, the "beyond a doubt" finding of a mortality rate up...
Wilson disease patients without cirrhosis at diagnosis generally have good long-term prognoses, but the presence of cirrhosis on diagnosis of this rare condition necessitates transplant in up to 13%...